| 沈晓霞.参麦注射液对NSCLC靶向耐药患者靶向联合化疗期间免疫细胞、细胞因子及肿瘤标记物的影响[J].浙江中西医结合杂志,2021,31(11): |
| 参麦注射液对NSCLC靶向耐药患者靶向联合化疗期间免疫细胞、细胞因子及肿瘤标记物的影响 |
| Effect of Shenmai Injection on immune cells, cytokines and tumor markers in patients with NSCLC during targeted combined chemotherapy |
| 投稿时间：2020-12-21 修订日期：2021-10-12 |
| DOI： |
| 中文关键词: 关键词：参麦注射液、NSCLC、耐药、化疗、免疫细胞、细胞因子、肿瘤标记物 |
| 英文关键词:Key words: shenmai injection, nsclc, drug resistance, chemotherapy, immune cells, cytokines, tumor markers |
| 基金项目:参麦注射液对NSCLC靶向耐药患者靶向联合化疗期间免疫细胞、细胞因子及肿瘤标记物的影响,浙江省医学会临床科研资金项目,项目编号：2019zyc-A25 |
|
| 摘要点击次数: 602 |
| 全文下载次数: 9 |
| 中文摘要: |
| 摘要 目的：分析参麦注射液对非小细胞肺癌（NSCLC）靶向耐药患者靶向联合化疗期间免疫细胞、细胞因子及肿瘤标记物的影响。方法：选取2020年1月~2020年7月在我院进行治疗的NSCLC患者50例，按照随机数字表法随机分为研究组与对照组，每组患者25例。对照组给予吉西他滨+顺铂治疗，研究组在对照组基础上给予参麦注射液治疗，以3周为一疗程，连续治疗6周。比较两组患者基本资料、临床疗效、免疫指标、细胞因子及肿瘤标记物变化，比较两组毒副反应发生情况。结果：与对照组对比，研究组患者疾病有效率及控制率均有所升高，但无明显差异（P>0.05）。与治疗前对比，治疗后，两组患者水平CD8+明显降低，且研究组明显低于对照组（P<0.05）；NK、CD3+、CD4+、CD4+/CD8+水平均明显升高，且研究组明显高于对照组（P<0.05）。与治疗前对比，治疗后，两组患者IL-10、IL-6及CEA、CA125、CYFRA21-1、NSE、SCC-Ag水平均明显降低，且研究组明显低于对照组；IL-2、TNF-、IFN-γ明显升高，且研究组明显高于对照组（P<0.05）。与对照组对比，研究组患者毒副反应发生率明显降低（P<0.05）。结论：参麦注射液联合化疗能够明显提高患者的免疫功能，有效控制肿瘤的发展，降低毒副反应的发生。 |
| 英文摘要: |
| Objective: To analyze the effect of Shenmai Injection on immune cells, cytokines and tumor markers in patients with non-small cell lung cancer (NSCLC) during targeted chemotherapy. squareMethods: Methods: 50 patients with NSCLC treated in our hospital from January 2020 to July 2020 were randomly divided into study group and control group, 25 cases in each group. The control group was treated with gemcitabine and cisplatin, and the study group was treated with Shenmai Injection on the basis of the control group, with 3 weeks as a course of treatment for 6 consecutive weeks. The basic data, clinical efficacy, immune indexes, cytokines and tumor markers were compared between the two groups.Results: Compared with the control group, the effective rate and control rate of the study group were increased, but there was no significant difference (P > 0.05). Compared with before treatment, after treatment, the level of CD8 + in the two groups was significantly lower than that in the control group (P < 0.05); the levels of NK, CD3 +, CD4 +, CD4 + / CD8 + in the study group were significantly higher than those in the control group (P < 0.05). Compared with before treatment, after treatment, the levels of IL-10, IL-6, CEA, CA125, CYFRA21-1, NSE and SCC Ag in the two groups were significantly lower than those in the control group, and the levels of IL-2, TNF - and IFN - γ in the study group were significantly higher than those in the control group (P < 0.05). Compared with the control group, the incidence of adverse reactions in the study group was significantly lower (P < 0.05).Conclusion:Shenmai injection combined with chemotherapy can significantly improve the immune function of patients, effectively control the development of tumor, and reduce the occurrence of adverse reactions. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
